Thermo Fisher Scientific Inc.
TMOThermo Fisher Scientific Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is already 4 weeks into its uptrend — timing risk, not thesis risk.
The price is in a confirmed uptrend (4 weeks in) while the P/E sits at the 37th percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +9.2% year on year, and 130% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Thermo Fisher Scientific Inc. trades at $565, in a confirmed uptrend and 4 weeks into that stage. That is +6.3% against its own 200-day average. It sits at 67% of a 52-week range of $438 to $626. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 3 straight weeks.
Today the stock is in a confirmed uptrend — week 4 of stage 2. At $565 it trades +6.3% versus its 200-day average and sits at 67% of its 52-week range ($438–$626).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +270% while the S&P 500 moved +263% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 3 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Thermo Fisher Scientific Inc. trades at 30.4× P/E, mid-range by its own standards (37th percentile). Its long-run median P/E is 32.2×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 30.4× is mid-range by its own standards (37th percentile), against a long-run median of 32.2× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +7.3% against a +22.0% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +1.0%/yr price move, ~+7.5%/yr came from earnings growth and ~−6.5 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Thermo Fisher Scientific Inc. reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE holding at 8.5% — the per-curve reads carry the story. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +3.9% | −0.3% | — | — |
| Profit | +6.0% | −1.8% | — | — |
| EPS | +7.3% | +0.2% | — | — |
| Stock price | +22.0% | +1.0% | +1.0% | +13.6% |
4-Factor Sector Score
46.3/100 — rank 18 of 30 in Diagnostics & Research · 58% evidence confidence
Thermo Fisher Scientific Inc. scores 46.3 out of 100 against the 30 companies it is compared with in Diagnostics & Research, ranking 18. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 17.5 + 14.2 + 10.7 + 3.9 = 46.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Thermo Fisher Scientific Inc. reported $11.0 B of revenue in the Mar 26 quarter, +6.3% year on year. That is the 7th straight quarter of year-on-year growth. Over 4 years it has compounded at 3.2% a year. The last full year, FY25, came in at $44.6 B. The last four reported quarters add to $45.2 B.
FY25 revenue came in at $44.6 B (+3.9% on the year), capping 4 years at 3.2% compound. The latest quarter (Mar 26) printed $11.0 B, +6.3% year on year — the 7th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +5.4% growth against the decade's 3.2% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +5.4% over the last 4 quarters against +3.1%/yr over the last 8 — stabilising; TTM profit +4.7% vs +7.1%/yr — stabilising.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Thermo Fisher Scientific Inc.'s operating margin is 16.9% in the Mar 26 quarter, +0.3 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 16.0% to 25.6%. The current quarter sits inside that band.
The latest quarter's operating margin is 16.9%, +0.3 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 16.0%–25.6%.
Why the margin moved: operating margin went +0.3 pp year on year while gross margin went −0.7 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Thermo Fisher Scientific Inc. earned $1.7 B of net profit in the Mar 26 quarter, +9.2% year on year. It is the 2nd consecutive quarter of growth. Full-year FY25 profit was $6.8 B. The 4-year compound rate is −3.3%. That is 15.1% of the quarter's revenue. The same quarter a year earlier earned $1.5 B.
Mar 26 profit was $1.7 B, +9.2% year on year — the 2nd consecutive quarter of growth. On the full year, FY25 printed $6.8 B (+6.0%), and the 4-year compound rate is −3.3%.
Why profit moved: revenue contributed +6.3% and the margin +0.3 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +4.6% vs revenue +5.4%. Profit and revenue are moving roughly in step.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 130% of Thermo Fisher Scientific Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $7.8 B of operating cash against $6.8 B of profit. After $1.5 B of capital spending, $6.3 B was left as free cash.
FY25: operating cash of $7.8 B against reported profit of $6.8 B, leaving free cash of $6.3 B after $1.5 B of capital spending. Across the last 3 fiscal years the conversion rate is 130% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Thermo Fisher Scientific Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $4.0 B over the last 3 years. Averaged over those years that is 3.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $4.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Thermo Fisher Scientific Inc. earns a ROE of 13% in FY25. Return on invested capital clears the cost of that capital by +0.9 percentage points, so growth here adds value rather than only size. The wiring behind it is 15.2% net margin on 0.40× asset turns.
FY25 ROE is 13%.
Why the return is what it is — the wiring (FY25): 15.2% net margin × 0.40× asset turns × 2.06× balance-sheet leverage ≈ 12.5% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 8.8% − 7.9% = a +0.9 pp spread. The 7.9% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Thermo Fisher Scientific Inc. paid $1.76 per share over the last four reported quarters, up 9.3% on a year ago. The most recent declaration was $0.47 for Mar 26. Against the current price of $565 that is a trailing yield of 0.31%, measured on dividends already paid rather than on a forecast.
Thermo Fisher Scientific Inc. paid $1.76 per share across the last four reported quarters, most recently $0.47 for Mar 26. That is up 9.3% against the same quarter a year earlier. Against the current price of $565 the trailing twelve months work out to 0.31% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Thermo Fisher Scientific Inc. carries total debt of $42.5 B against shareholder equity of $52.8 B as of Jun 26, a debt-to-equity of 0.81. On the annual view that ratio went from 0.85 in FY21 to 0.74 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Jun 26: total debt of $42.5 B against shareholder equity of $52.8 B — a debt-to-equity of 0.81. On the annual view, debt-to-equity went from 0.85 (FY21) to 0.74 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
1.4% of Thermo Fisher Scientific Inc.'s tradable float is currently sold short — the crowd is not positioned against this stock. At typical trading volumes those positions would take about 2.5 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 1.4% of the float is sold short, and at typical trading volumes it would take about 2.5 days to buy those positions back. The crowd is not positioned against this stock. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Thermo Fisher Scientific Inc.: the Z-score reads 3.44. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 3.44 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 3.44.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Medpace Holdings, Inc.MEDP | 60.6/100Thin evidence · provisional58% evidence | TURNING | 21.1/35 Revenue — · PAT — · OPM change -0.3 pp 45% evidence | 21.3/25 ROCE 30.2% · OPM 20% 76% evidence | 10.5/20 P/E 31× · PEG — 15% evidence | 7.7/20 RS sector -13.3% · RS bench 0.3% · 1Y 32.4%3 of 12 weeks ahead 100% evidence |
| Exact sum: 21.1 + 21.3 + 10.5 + 7.7 = 60.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Agilent Technologies, Inc.A | 56.8/100Mixed-positive evidence85% evidence | BREAKING OUT | 22.5/35 Revenue 9.1% · PAT 21.3% · OPM change 3.7 pp 95% evidence | 16.1/25 ROCE 3.8% · OPM 21.7% 76% evidence | 14.4/20 P/E 23.2× · PEG 1.01 65% evidence | 3.8/20 RS sector -17.5% · RS bench -4.3% · 1Y 21.4%6 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 16.1 + 14.4 + 3.8 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Illumina, Inc.ILMN | 56.5/100Thin evidence · provisional58% evidence | LEADER | 18.1/35 Revenue — · PAT — · OPM change 3.4 pp 45% evidence | 14.3/25 ROCE 5.1% · OPM 19.2% 76% evidence | 10.3/20 P/E 32.9× · PEG — 15% evidence | 13.8/20 RS sector 18.4% · RS bench 36.7% · 1Y 114.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 14.3 + 10.3 + 13.8 = 56.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Adaptive Biotechnologies CorporationADPT | 55.5/100Thin evidence · provisional55% evidence | BREAKING OUT | 21.6/35 Revenue — · PAT — · OPM change 29.3 pp 45% evidence | 5.7/25 ROCE -3.3% · OPM -27.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 18.2/20 RS sector 19.2% · RS bench 37.1% · 1Y 101.2%9 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 5.7 + 10 + 18.2 = 55.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5NeoGenomics, Inc.NEO | 54.7/100Thin evidence · provisional58% evidence | BREAKING OUT | 21.0/35 Revenue — · PAT — · OPM change 6.8 pp 45% evidence | 6.0/25 ROCE -0.8% · OPM -9.8% 76% evidence | 9.0/20 P/E 134× · PEG — 15% evidence | 18.7/20 RS sector 22.1% · RS bench 39.9% · 1Y 180.9%10 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 6 + 9 + 18.7 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6IDEXX Laboratories, Inc.IDXX | 54.1/100Mixed-positive evidence81% evidence | TURNING | 22.8/35 Revenue 13.1% · PAT 22.4% · OPM change 0.1 pp 83% evidence | 20.1/25 ROCE 17.4% · OPM 31.8% 76% evidence | 10.1/20 P/E 41.4× · PEG 1.62 65% evidence | 1.1/20 RS sector -27.4% · RS bench -15.5% · 1Y -10.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.8 + 20.1 + 10.1 + 1.1 = 54.1 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -27.4% and the one-year return is -10.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 7Mettler-Toledo International Inc.MTD | 53.9/100Thin evidence · provisional58% evidence | TURNING | 17.4/35 Revenue — · PAT — · OPM change -0.8 pp 45% evidence | 18.4/25 ROCE 12.9% · OPM 23.9% 76% evidence | 10.6/20 P/E 28.8× · PEG — 15% evidence | 7.5/20 RS sector -15.6% · RS bench -2% · 1Y 14.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17.4 + 18.4 + 10.6 + 7.5 = 53.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Quest Diagnostics IncorporatedDGX | 52.5/100Thin evidence · provisional58% evidence | TURNING | 17.0/35 Revenue — · PAT — · OPM change 0.8 pp 45% evidence | 14.7/25 ROCE 3.2% · OPM 13.8% 76% evidence | 11.2/20 P/E 22.5× · PEG — 15% evidence | 9.6/20 RS sector -6.6% · RS bench 8.8% · 1Y 32.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 14.7 + 11.2 + 9.6 = 52.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Natera, Inc.NTRA | 51.3/100Mixed-positive evidence61% evidence | BREAKING OUT | 21.3/35 Revenue 36.6% · PAT — · OPM change 2.4 pp 62% evidence | 5.4/25 ROCE -5.5% · OPM -13.4% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.6/20 RS sector 1.4% · RS bench 17% · 1Y 81.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.3 + 5.4 + 10 + 14.6 = 51.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Charles River Laboratories International, Inc.CRL | 50.7/100Mixed-positive evidence64% evidence | BREAKING OUT | 18.0/35 Revenue 0.1% · PAT — · OPM change 4.4 pp 62% evidence | 11.7/25 ROCE 1.8% · OPM 12% 76% evidence | 8.8/20 P/E 427.2× · PEG — 15% evidence | 12.2/20 RS sector -0.8% · RS bench 14.6% · 1Y 57.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 11.7 + 8.8 + 12.2 = 50.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Labcorp Holdings Inc.LH | 50.7/100Thin evidence · provisional58% evidence | TURNING | 17.5/35 Revenue — · PAT — · OPM change 1.1 pp 45% evidence | 13.3/25 ROCE 2.8% · OPM 10.8% 76% evidence | 11.1/20 P/E 23.2× · PEG — 15% evidence | 8.8/20 RS sector -11.2% · RS bench 3.5% · 1Y 17.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 13.3 + 11.1 + 8.8 = 50.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Twist Bioscience CorporationTWST | 50.6/100Mixed-positive evidence61% evidence | BREAKING OUT | 16.7/35 Revenue 17.8% · PAT — · OPM change 3.4 pp 62% evidence | 4.7/25 ROCE -8.5% · OPM -41.4% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 19.2/20 RS sector 59.8% · RS bench 84.2% · 1Y 287.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 4.7 + 10 + 19.2 = 50.6 · Decision use: Price leads the evidence: RS versus the benchmark is 84.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 13IQVIA Holdings Inc.IQV | 50.0/100Thin evidence · provisional58% evidence | BREAKING OUT | 16.0/35 Revenue — · PAT — · OPM change -0.6 pp 45% evidence | 13.7/25 ROCE 2.4% · OPM 12.4% 76% evidence | 10.8/20 P/E 24× · PEG — 15% evidence | 9.5/20 RS sector -10.1% · RS bench 4% · 1Y 26.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 16 + 13.7 + 10.8 + 9.5 = 50 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Veracyte, Inc.VCYT | 49.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 21.2/35 Revenue — · PAT — · OPM change 13.8 pp 45% evidence | 11.0/25 ROCE 1.7% · OPM 16.3% 76% evidence | 9.5/20 P/E 41.7× · PEG — 15% evidence | 7.5/20 RS sector -9.6% · RS bench 4.2% · 1Y 69.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 11 + 9.5 + 7.5 = 49.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15CareDx, Inc.CDNA | 48.7/100Thin evidence · provisional52% evidence | BREAKING OUT | 15.5/35 Revenue — · PAT — · OPM change 16.8 pp 45% evidence | 4.7/25 ROCE -28.5% · OPM 1% 76% evidence | 11.5/20 P/E 13.8× · PEG — 15% evidence | 17.0/20 RS sector 81.9% · RS bench 108.8% · 1Y 293.4%12 of 12 weeks ahead 70% evidence |
| Exact sum: 15.5 + 4.7 + 11.5 + 17 = 48.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Guardant Health, Inc.GH | 48.4/100Thin evidence · provisional55% evidence | BREAKING OUT | 16.5/35 Revenue — · PAT — · OPM change 14.4 pp 45% evidence | 4.3/25 ROCE -9.7% · OPM -40.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 17.6/20 RS sector 25% · RS bench 43.3% · 1Y 194.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 4.3 + 10 + 17.6 = 48.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Sotera Health CompanySHC | 48.1/100Mixed-negative evidence64% evidence | BREAKING OUT | 19.3/35 Revenue 7.3% · PAT 100% · OPM change 4.7 pp 62% evidence | 14.3/25 ROCE 2.6% · OPM 27.1% 76% evidence | 9.9/20 P/E 35× · PEG — 15% evidence | 4.6/20 RS sector -14.7% · RS bench -1% · 1Y 29.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 14.3 + 9.9 + 4.6 = 48.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Thermo Fisher Scientific Inc.this pageTMO | 46.3/100Thin evidence · provisional58% evidence | TURNING | 17.5/35 Revenue — · PAT — · OPM change 0.3 pp 45% evidence | 14.2/25 ROCE 2.2% · OPM 16.9% 76% evidence | 10.7/20 P/E 27.6× · PEG — 15% evidence | 3.9/20 RS sector -16.8% · RS bench -3.6% · 1Y 22.6%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 14.2 + 10.7 + 3.9 = 46.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Qiagen N.V.QGEN | 45.7/100Mixed-negative evidence71% evidence | TURNING | 15.7/35 Revenue 4.8% · PAT 100% · OPM change -6.8 pp 83% evidence | 12.9/25 ROCE 1.6% · OPM 17.1% 76% evidence | 11.4/20 P/E 20.9× · PEG — 15% evidence | 5.7/20 RS sector -27.4% · RS bench -15.6% · 1Y -16.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 12.9 + 11.4 + 5.7 = 45.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Danaher CorporationDHR | 44.5/100Thin evidence · provisional58% evidence | TURNING | 18.5/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 13.8/25 ROCE 1.4% · OPM 22.6% 76% evidence | 10.1/20 P/E 34.8× · PEG — 15% evidence | 2.1/20 RS sector -26% · RS bench -14.1% · 1Y -2.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18.5 + 13.8 + 10.1 + 2.1 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Castle Biosciences, Inc.CSTL | 43.2/100Thin evidence · provisional52% evidence | TURNING | 18.9/35 Revenue — · PAT — · OPM change 9.7 pp 45% evidence | 6.8/25 ROCE -0.6% · OPM -22% 76% evidence | 9.3/20 P/E 43× · PEG — 15% evidence | 8.2/20 RS sector -12.6% · RS bench 0.4% · 1Y 61.1%2 of 12 weeks ahead 70% evidence |
| Exact sum: 18.9 + 6.8 + 9.3 + 8.2 = 43.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Revvity, Inc.RVTY | 42.8/100Thin evidence · provisional58% evidence | BREAKING OUT | 15.2/35 Revenue — · PAT — · OPM change -1.9 pp 45% evidence | 11.5/25 ROCE 0.7% · OPM 10.7% 76% evidence | 9.4/20 P/E 42.6× · PEG — 15% evidence | 6.7/20 RS sector -11.4% · RS bench 2.7% · 1Y 28.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 15.2 + 11.5 + 9.4 + 6.7 = 42.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23OPKO Health, Inc.OPK | 42.8/100Thin evidence · provisional52% evidence | TURNING | 21.2/35 Revenue — · PAT — · OPM change 3.7 pp 45% evidence | 7.1/25 ROCE -0.4% · OPM -41.1% 76% evidence | 10.2/20 P/E 33.2× · PEG — 15% evidence | 4.3/20 RS sector -23.4% · RS bench -10.7% · 1Y 4.8%9 of 12 weeks ahead 70% evidence |
| Exact sum: 21.2 + 7.1 + 10.2 + 4.3 = 42.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24GRAIL, Inc.GRAL | 38.8/100Mixed-negative evidence61% evidence | BREAKING OUT | 21.2/35 Revenue 19.9% · PAT — · OPM change 149.6 pp 62% evidence | 4.7/25 ROCE -4.9% · OPM -332.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.9/20 RS sector -16.4% · RS bench -4.6% · 1Y 121.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 4.7 + 10 + 2.9 = 38.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25ICON Public Limited CompanyICLR | 38.7/100Thin evidence · provisional58% evidence | BREAKING OUT | 13.8/35 Revenue — · PAT — · OPM change -2.8 pp 45% evidence | 10.5/25 ROCE 1% · OPM 8.5% 76% evidence | 8.9/20 P/E 310.2× · PEG — 15% evidence | 5.5/20 RS sector -20.7% · RS bench -8.3% · 1Y -1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 10.5 + 8.9 + 5.5 = 38.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Waters CorporationWAT | 38.3/100Thin evidence · provisional58% evidence | BREAKING OUT | 12.0/35 Revenue — · PAT — · OPM change -28.1 pp 45% evidence | 9.6/25 ROCE -0.4% · OPM -3.7% 76% evidence | 9.8/20 P/E 38.7× · PEG — 15% evidence | 6.9/20 RS sector -11.4% · RS bench 2.6% · 1Y 40.9%10 of 12 weeks ahead 100% evidence |
| Exact sum: 12 + 9.6 + 9.8 + 6.9 = 38.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27RadNet, Inc.RDNT | 37.9/100Mixed-negative evidence64% evidence | TURNING | 17.9/35 Revenue 14.8% · PAT 100% · OPM change 0.9 pp 62% evidence | 8.3/25 ROCE -0.8% · OPM -4.2% 76% evidence | 8.6/20 P/E 1746× · PEG — 15% evidence | 3.1/20 RS sector -21.2% · RS bench -8.5% · 1Y 29.8%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 8.3 + 8.6 + 3.1 = 37.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Personalis, Inc.PSNL | 37.0/100Thin evidence · provisional55% evidence | BREAKING OUT | 7.3/35 Revenue -27.6% · PAT — · OPM change -122 pp 62% evidence | 3.7/25 ROCE -12.1% · OPM -207.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 16.0/20 RS sector 24.8% · RS bench 42.5% · 1Y 199.8%11 of 12 weeks ahead 70% evidence |
| Exact sum: 7.3 + 3.7 + 10 + 16 = 37 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29GeneDx Holdings Corp.WGS | 30.9/100Adverse evidence64% evidence | TURNING | 12.6/35 Revenue 33.8% · PAT — · OPM change -51 pp 62% evidence | 4.1/25 ROCE -14.4% · OPM -56.2% 76% evidence | 8.5/20 P/E 2693.5× · PEG — 15% evidence | 5.7/20 RS sector -43.7% · RS bench -34.9% · 1Y -32.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 12.6 + 4.1 + 8.5 + 5.7 = 30.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30BillionToOne, Inc.BLLN | 58.3/100Thin evidence · provisional44% evidence | BREAKING OUT | 26.0/35 Revenue 99.4% · PAT — · OPM change 20.4 pp 62% evidence | 13.1/25 ROCE 3.9% · OPM 16.5% 76% evidence | 9.2/20 P/E 60.9× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —11 of 12 weeks ahead 0% evidence |
| Exact sum: 26 + 13.1 + 9.2 + 10 = 58.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Thermo Fisher Scientific Inc.'s stock price today?
Thermo Fisher Scientific Inc. trades at $565, +22.0% over the past year. The company is valued at $209 B. The stock sits at 67% of its 52-week range of $438–$626, +6.3% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 4 weeks in. — as of 5 August 2026.
What were Thermo Fisher Scientific Inc.'s latest quarterly results?
Thermo Fisher Scientific Inc. reported revenue of $11.0 B and net profit of $1.7 B for the Mar 26 quarter. Revenue rose 6.3% and profit rose 9.2% year on year. Earnings per share were $4.43. The operating margin was 16.9%, 0.3 pp higher than a year earlier. — as of 5 August 2026.
What is Thermo Fisher Scientific Inc.'s revenue?
Thermo Fisher Scientific Inc. reported revenue of $11.0 B in the Mar 26 quarter, +6.3% year on year. For the full FY25 fiscal year, revenue was $44.6 B (+3.9%). Over the last 4 years revenue compounded at 3.2% a year. — as of 5 August 2026.
What is Thermo Fisher Scientific Inc.'s profit?
Thermo Fisher Scientific Inc. earned $1.7 B of net profit in the Mar 26 quarter, +9.2% year on year — the 2nd straight quarter of growth. Full-year FY25 profit was $6.8 B. The operating margin ran 16.9% in the latest quarter. — as of 5 August 2026.
What is Thermo Fisher Scientific Inc.'s market cap?
Thermo Fisher Scientific Inc.'s market capitalisation is $209 B at a stock price of $565. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is Thermo Fisher Scientific Inc.'s P/E ratio?
Thermo Fisher Scientific Inc. trades at a P/E of 30.4×, at the 37th percentile of its own 4-year range, against a long-run median of 32.2×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does Thermo Fisher Scientific Inc. pay a dividend?
Yes — Thermo Fisher Scientific Inc. declared $0.47 per share for Mar 26, and $1.76 per share across the last four reported quarters. The latest quarter is up 9.3% on the same quarter a year earlier. — as of 5 August 2026.
What is Thermo Fisher Scientific Inc.'s dividend per share?
Thermo Fisher Scientific Inc.'s most recently declared dividend is $0.47 per share for Mar 26, giving $1.76 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
What is Thermo Fisher Scientific Inc.'s dividend yield?
Thermo Fisher Scientific Inc.'s trailing dividend yield is 0.31%: $1.76 declared per share across the last four reported quarters, against a share price of $565. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.
Is Thermo Fisher Scientific Inc. overvalued?
On its own history, Thermo Fisher Scientific Inc. looks mid-range against its own history: its P/E of 30.4× sits at the 37th percentile of its 4-year range (long-run median 32.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
Is Thermo Fisher Scientific Inc. growing?
Yes — Thermo Fisher Scientific Inc. is growing: latest-quarter revenue +6.3% year on year, profit +9.2%, and the margin +0.3 pp at 16.9%. The 4-year compound rates are 3.2% (revenue) and −3.3% (profit). The earnings engine currently reads: improving — as of 5 August 2026.
How is Thermo Fisher Scientific Inc. performing?
Thermo Fisher Scientific Inc. is in a confirmed uptrend, 4 weeks in. Its latest quarter's revenue rose 6.3% and profit rose 9.2% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Thermo Fisher Scientific Inc. in?
Mixed — no clean majority across the growth curves, ROCE holding at 8.5% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +5.4% latest, profit growth +4.7% latest, eps growth +6.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Thermo Fisher Scientific Inc. in an uptrend?
Yes — the price is in a confirmed uptrend (week 4 of stage 2), trading +6.3% versus its 200-day average and at 67% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Thermo Fisher Scientific Inc. beating the market?
On recent form, yes — Thermo Fisher Scientific Inc. has been ahead of the S&P 500 on a trailing-13-week view for 3 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +270% against the S&P 500's +263% — ahead of the index over the full window. — as of 5 August 2026.
Will Thermo Fisher Scientific Inc.'s stock price go up?
This page publishes no price forecast for Thermo Fisher Scientific Inc. What it measures instead: the stock price is $565, the price is in a confirmed uptrend 4 weeks in. Its P/E of 30.4× sits at the 37th percentile of its own 4-year range. — as of 5 August 2026.
Is the market betting against Thermo Fisher Scientific Inc.?
No — short interest is 1.4% of Thermo Fisher Scientific Inc.'s tradable float, about 2.5 days to cover at typical volumes. That is a low reading: the crowd is not positioned against this stock. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Thermo Fisher Scientific Inc. have too much debt?
It is moderate — Thermo Fisher Scientific Inc.'s debt-to-equity is 0.81. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is Thermo Fisher Scientific Inc.'s capex?
Thermo Fisher Scientific Inc. spent $4.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $1.5 B. — as of 5 August 2026.
What is Thermo Fisher Scientific Inc.'s cash flow?
Thermo Fisher Scientific Inc. generated $7.8 B of operating cash flow in FY25 and $6.3 B of free cash flow after $1.5 B of capital spending. Reported profit that year was $6.8 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Thermo Fisher Scientific Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 130% of Thermo Fisher Scientific Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $7.8 B against reported profit of $6.8 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Thermo Fisher Scientific Inc.?
On the balance sheet, the Z-score reads 3.44 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is Thermo Fisher Scientific Inc. in its business cycle?
Thermo Fisher Scientific Inc.'s FY25 operating margin was 17.4%, against a 5-year band of 16.0%–25.6%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 16.9%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Thermo Fisher Scientific Inc. story?
Biggest watch item: the price is already 4 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Thermo Fisher Scientific Inc. a stock worth studying right now?
This is not investment advice. The machine read: Thermo Fisher Scientific Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.